Inflammatory and Immune Pathways Driving Tumor Necrosis Factor Inhibitor Resistance in Ulcerative Colitis

Ulcerative colitis (UC) is a chronic immune-mediated inflammatory disease characterized by dysregulated mucosal immunity in genetically susceptible individuals exposed to environmental and microbial triggers. Tumor necrosis factor-alpha (TNF-α) antagonists have transformed the management of moderately-to-severely active UC and remain a cornerstone of therapy, although approximately one third of patients demonstrate primary non-response and up to half experience secondary loss of response over time. Historically, treatment failure has been attributed to pharmacokinetic factors such as inadequate drug exposure or immunogenicity. Increasing evidence suggests that TNF-α resistance is frequently mediated by pharmacodynamic factors, including cytokine redundancy and non-TNF inflammatory circuits. Among the most prominent mechanisms are activation of the IL-6 signaling axis, stromal cytokines such as oncostatin M, IL-23-driven Th17 inflammation, and IL-1-mediated innate immune responses. More exploratory mechanisms include perturbations in B-cell and plasmablast biology, transcriptional signatures associated with myeloid activation, genetic susceptibility pathways such as TREM-1 signaling, and microbiome-driven metabolic dysfunction. Emerging data also suggest a role for neutrophil extracellular traps. Although biologically plausible, the clinical relevance and therapeutic implications of several of these emerging mechanisms remain to be established. Advances in transcriptomics, single-cell sequencing, and systems biology approaches have further highlighted the heterogeneity of inflammatory pathotypes in UC and the importance of precision medicine strategies. Understanding the molecular determinants of TNF-α resistance could inform more rational therapeutic sequencing, guide optimization of existing therapies, and identify novel targets for combination or next-generation treatments aimed at improving outcomes in patients with difficult-to-treat UC. In this review, we highlight key mechanisms of TNF-α non-response, identify potentially druggable therapeutic targets within this framework, and define future directions for advancing care in patients with UC who experience TNF-α non-response.